Comparison of analgesic effects of duloxetine and pregabalin in burn patients
Phase 3
Recruiting
- Conditions
- Burn injury.Burn and corrosion, body region unspecified
- Registration Number
- IRCT20150609022637N6
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Burn patients aged 15-75 years
Exclusion Criteria
Consuming monoamine oxidase inhibitor drugs, three cyclic antidepressant drugs, selective serotonin reuptake inhibitors, venlafaxine, tramadol, buspirone, triptan drugs, lithium, ondansetron, antiepileptic drugs, linezolid, potent inhibitors of cytochrome P450 (CYP450) 2D6 and CYP450 1A2
Creatinine clearance less than 60 ml per minute
Hepatic failure or elevated liver enzymes
Epilepsy
Depression
Bipolar mood disorder
Thrombocytopenia
Hyponatremia
Heart failure
Pregnancy
Lactation
Uncontrolled open angle glaucoma
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of background pain. Timepoint: At the initiation of the study and every other day. Method of measurement: Severity item of the neuropathic pain scale.
- Secondary Outcome Measures
Name Time Method Quality of the background pain. Timepoint: At the initiation of the study and every other day. Method of measurement: Other items of the neuropathic pain scale.;Severity of procedural pain. Timepoint: At the initiation of the study and every other day. Method of measurement: Visual analog scale.;Anxiety. Timepoint: At baseline and before each procedure. Method of measurement: Burn Specific Pain Anxiety Scale.